SIG MMG 338 Program Series

Posts Tagged ‘B-Temia’

B-TEMIA Doubles its Commercialization and Manufacturing Capacities

Friday, October 28th, 2016

Québec City, QC | October 25, 2016 – B-TEMIA Inc., the developer and manufacturer of the Dermoskeleton™ mobility assistive technology announces that it has recently opened its new head office in St-Augustin, Québec City. The new facility will enable the Company to double its commercialization and manufacturing capacities.

“In 2016, we decisively transitioned the Company towards the full commercialization of our Keeogo™ walking assistive device in Canada, while advancing the groundwork for its future introduction in the US market. It became clear that in order to service our customers more effectively and maintain our growth, we needed to move to a new location,“ said Stéphane Bédard, Founder and CEO of B-TEMIA. “Regrouping all our operations into one larger working space will significantly increase our capability to mature our industrial phase, improve our operational performance as well as upgrade our employees’ working environment ,” added Mr. Bedard.

B-TEMIA has now put in place all the necessary resources to accelerate its commercialization efforts and make its exclusive Keeogo™ device available throughout Canada. With over 20 employees, the Company has recently added key operational skills in sales, customer service, regulatory and clinical management to support its growth in the Canadian market and the completion of the US Food and Drug Administration (FDA) clearance process.

B-TEMIA Initiates Pivotal Clinical Trial To Support Commercial Launch Of Keeogo In The U.S.

Tuesday, November 24th, 2015

– Partnering with three of the most reputable rehab centers in North America –

Quebec, November 23, 2015 – B-TEMIA Inc., the market leader in human augmentation, today announced that it has initiated a multi-centre pivotal clinical trial, aimed at demonstrating the superior clinical benefits and safety for home use of its powered assistive DemoskeletonTM technology, called Keeogo, for patients suffering from reduced mobility due to their medical conditions. Led by Principal Investigator, Dr. Chris A. McGibbon, PhD, from the University of New Brunswick’s, Faculty of Kinesiology and Institute of Biomedical Engineering, the study is expected to generate the required data to support the submission of a 510(k) pre-market notification to the U.S. Food and Drug Administration in 2016, a prerequisite to start commercialization in the United States.

“This is the first international clinical trial involving the DermoskeletonTM technology that aims at demonstrating the efficacy and safety of Keeogo™ during everyday community and home mobility use, something that has not been possible in the past with other exoskeleton technologies that were developed principally for use in a clinical rehabilitation setting,” stated Dr. Chris A. McGibbon.

As part of the trial, B-TEMIA has partnered with three of the most reputable rehabilitation institutions in North America: the Rehabilitation Institute of Chicago, the Spaulding Rehabilitation Hospital Boston, and the Toronto Rehabilitation Institute–UHN.

“This pivotal clinical trial will be key in supporting the commercial launch of KeeogoTM in the U.S. market. Based on earlier very positive pilot studies, we are confident that it will demonstrate how Keeogo™ could significantly improve the daily activities of those who suffer from disabilities that impact their mobility,” said Mr. Stéphane Bédard, President & CEO of B-TEMIA.

B-Temia And Sagem Sign A Partnership Agreement In The Field Of Exoskeletons For Industrial And Military Applications

Tuesday, November 10th, 2015

Québec and Boulogne-Billancourt, November 9, 2015

Canadian company B-Temia, Inc. and French company Sagem (Safran) today announced the signature of a technological and business development agreement concerning a new- generation of exoskeletons for industrial and military applications.

Exoskeletons are bio-mechanical and electronic structures worn on the body to assist and enhance people’s movements, or to restore mobility.

According to the terms of this agreement, Sagem and B-Temia will jointly develop and market new-generation exoskeletons. Sagem will contribute its long experience in the integration of complex systems, its innovative actuators and stabilization technologies. B- Temia, an exoskeleton technology leader, will contribute its experience in human robotics and artificial intelligence, based on its proprietary “Dermoskeleton” technology, already in production for the healthcare sector.

“B-Temia is very proud of this partnership with Sagem, focused on the development and production of our dermoskeleton products. This agreement confirms our company’s technology leadership, business value, and the credibility of our work addressing increased human mobility needs in both industrial and defense applications,” said Stéphane Bédard, President and CEO of B-Temia.

Martin Sion, Chief Executive Officer of Sagem, added, “Our collaboration with B-Temia will enable us to sustain new R&D work on exoskeletons. For Sagem, this is a very promising technology for industrial and military applications. In particular, our collaboration spotlights the dynamic mindset that Sagem seeks to deploy in the application of innovative dual technologies in conjunction with both startups and major corporations.”

B-TEMIA Appoints Mr. Steven Smith As Vice President Of Business Development

Tuesday, March 3rd, 2015

Quebec, March 3, 2015 – B-TEMIA Inc., a leader in the growing market of human augmentation, announces the appointment of Mr Steven Smith as Vice President Business Development. Mr Smith has extensive industry experience in the home medical equipment market and, in particular, in the commercialization of mobility devices that will be very valuable for the commercialization of Keeogo.

Mr Smith previously worked for the Canadian home medical equipment market leader Shoppers Home Healthcare. Mr Smith joined Shoppers in 1996 and was instrumental in the growth of their business. “I am pleased to join B-TEMIA’s team and to be part of the commercialization of Keeogo. It is an exciting moment for me to have the chance to share my knowledge with this highly talented team”, stated Mr Smith.

In addition, B-TEMIA has appointed Mr. Marc-André Côté as Senior Director, Regulatory Affairs & Quality Management. As a senior regulatory affairs professional, and a former government regulator, Mr. Côté has brought numerous medical devices to regulatory approval. Mr. Côté will be a critical asset for B-TEMIA in the pursuit of its regulatory obligations with the FDA, Health Canada and regulatory bodies around the globe.

“I am convinced that the addition of these pivotal resources to the company’s corporate structure will help us to maintain our leadership position, expand our competencies and reinforce our team spirit which is our most valuable asset”, comments Mr. Stéphane Bédard, President and CEO of BTEMIA.

SOFIC 2014 – Revision Military

Wednesday, May 21st, 2014

Revision Military is debuting two new products at this year’s SOFIC, the Expanded Batlskin Head Protection System, and the Prowler Military dermoskeleton which was developed in collaboration with B-TEMIA Inc.


Batlskin Viper Front Mount

Revision’s Viper Front Mount features an interchangeable center piece system which allows the user to swap the receiver component and utilize various NVG interface plates. The Front Mount also acts as the MPAS platform, allowing integration of the full line of Batlskin Viper components such as the Interlocking Long Rails and Mandible Guards.


Batlskin Viper Interlocking Long Rails

Revision’s Viper Interlocking Long Rails attach to the Front Mount and allow for quick and easy attachment of cameras, lights, and other head borne accessories. The rails are sized specifically to fit small, medium, large, or extra-large helmets. Now available to order.


Batlskin Viper High Cut Helmets

Revision’s Viper A1 and P2 High Cut Helmets are designed for optimal compatibility with communications headsets. The ACH-shaped Viper A1 High Cut is now available in all sizes. The Viper P2 High Cut will be available in early Summer.


Batlskin Viper Three-Position Visor

Revision’s Viper Three-Position visor clips into the Front Mount with a simple, one-handed movement, and can be worn in three configurations: locked, vented, or up. The Visor features high-impact protection and maximum field-of-view while remaining scratch, fog, and chemical resistant. An optional gasket provides a seal between the Visor and helmet. The Viper Visor will be available in early June.


Batlskin Viper Mandible Guards

Revision’s updated Mandible Guard provides best-in-class lower-face protection in a strapless design that’s lightweight and quickly attaches to the Front Mount without the use of tools. The Guard is easily tilted downwards in varying degrees from improved sight compatibility, eating, and drinking. Pressing the mandible against the chest resets it to its original position. The Mandible Guard will be available in early Summer.


Click to view .pdf
Prowler Augmentation System

The B-TEMIA / Revision Prowler is a near skin, lower body motorized soldier protection device worn on both legs. It is designed to increase the metabolic energy reserve of soldiers while preventing short and long term musculoskeletal injuries. The Prowler distributes the load across the entire body from the upper body to the lower legs, circumventing the load around the knee joint which is proven to reduce applied stress to the knee by 1/3 under combat load conditions. The Prowler has been tested through the US Army NSRDEC Human Augmentation Program and SOCOM’s TALOS Program.

B-TEMIA Featured in Vanguard

Monday, May 28th, 2012

Canada’s Vanguard magazine featured B-TEMIA’s dermoskeleton.

Revision Eyewear Teams with B-Temia

Friday, March 11th, 2011

Revision is showing us more and more that they have transcended beyond just an eyewear company and are reaching out into many additional areas of Soldier protection. Earlier this week, they announced a deal with B-Temia to fund development of their first dermoskeleton, aimed at helping soldiers suffering from musculoskeletal injuries.

Since the term “dermoskeleton” is foreign to most of us, we thought it would be best to explain exactly what it is that they are talking about. From the B-Temia website, “A dermoskeleton mechanism is an automated orthopaedic supporting brace fully integrated onto a given joint-segment structure of a user’s body without any interaction with the environment such as ground contacts using, for example, instrumented insoles.

“Based in Canada and the United States as well as with a significant presence in Europe, Revision has proven to be a major player in the field of soldier protection and survivability. We are very proud to team up with a formidable industry player like Revision,” stated Stéphane Bédard, President and CEO of B-Temia.

Additionally, B-Temia Military, a subsidiary of B-Temia, has signed an international licensing agreement with Revision Military for the commercialization of its dermoskeletons. “We see musculoskeletal injuries and the associated non-deployment rates of soldiers caused by heavy load carriage as a costly and painful concern that military organizations around the world must address. The market potential for B-Temia’s dermoskeleton is tremendous. We are excited to add this innovative technology to our portfolio of purpose-built soldier equipment,” said Jonathan Blanshay, CEO of Revision.